+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative analysis of immune response indices in lung cancer



Comparative analysis of immune response indices in lung cancer



Voprosy Onkologii 31(1): 39-44



In 43 patients with cancer of the lung, a number of immunologic indexes were evaluated including lymphocyte response to PHA, lymphokine production, serum immunoglobulin levels and the regulatory effect of sera and T-lymphocytes on lymphokine production. No significant deficiency in T- and B-lymphocytes was registered in patients with stage I-III cancer, nor any rise in TG cell level was in evidence. The response to PHA was low; however, the capacity to produce lymphokines in the presence of allogeneic or autologous tumor antigens was unimpaired. Purified T- and TG-cells isolated from blood or tumor tissue suppressed immune response in leukocyte migration inhibition test. However, this effect was not related to the increase in levels of these cells in the circulation. The autologous sera of practically all tumor-sensitized patients exerted a blocking effect in vitro. This effect was related neither to levels of serum immunoglobulins, nor to those of blood TG cells.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039614715

Download citation: RISBibTeXText

PMID: 3156450


Related references

Comparative analysis of indices of immunologic response in lung cancer. Voprosy Onkologii (St Petersburg) 31(1): 39-44, 1985

Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials. Journal of Thoracic Oncology 14(8): 1440-1446, 2019

Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Medicine 97(33): E11936, 2018

Morphological manifestations of the immune response in breast cancer as indices of disorders of immune homeostasis, adequacy of treatment and evaluation of prognosis. Arkhiv Patologii 49(7): 83-87, 1987

Studies on the host immune response in cancer part 2 host immune response in lung cancer patients during chemo therapy. Okayama Igakkai Zasshi 90(7-8): 1055-1064, 1978

Tumor-antigen-specific humoral immune response of animals to anti-idiotypic antibodies and comparative serological analysis of patients with small-cell lung carcinoma. International Journal of Cancer 50(1): 86-92, 1992

Immune indices in tuberculosis, lung cancer and chronic pneumonias. Problemy Tuberkuleza 1993(4): 24-26, 1993

Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis. Thoracic Cancer 10(4): 607-623, 2019

Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials. Cancer Management and Research 11: 1623-1629, 2019

Analysis of first-line chemoresistance and prediction of chemo-response in non-small cell lung cancer by comparative genomic hybridization. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae 32(4): 389-393, 2010

Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants. Lung Cancer 115: 84-88, 2018

Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer A systematic review and network meta-analysis of 3024 participants. Lung Cancer 115: 84-88, 2018

Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review. International Journal of Molecular Sciences 20(9):, 2019

Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody. Annals of Oncology 28(11): 2893-2895, 2017

Bronchoalveolar lavage in lung cancer--diagnostic value and assessment of the anti-cancer immune response. Postepy Higieny i Medycyny Doswiadczalnej 67: 1119-1127, 2013